ABBV 706
Alternative Names: ABBV-706Latest Information Update: 25 Aug 2026
At a glance
- Originator AbbVie
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 02 Jul 2026 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater, Monotherapy) in Austria, Spain, Germany (IV) (NCT07365241)
- 02 Jul 2026 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater, Monotherapy) in Greece, Japan, Switzerland (IV) (NCT07365241)
- 02 Jul 2026 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater) (IV) (AbbVie pipeline; June 2026) (NCT07365241)